Mr Mark S. Cheffo > Dechert LLP > New York, United States > Lawyer Profile

Dechert LLP
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
United States
Mark S. Cheffo photo

Work Department

Product Liability and Mass Torts

Career

Mark S. Cheffo is co-chair of Dechert’s product liability and mass torts practice and has extensive experience serving as national coordinating and trial counsel in complex product liability, insurance and mass torts litigation. He acts for corporates and individuals in the pharmaceutical, medical device manufacturing, bioengineering, insurance and industrial products industries, amongst others. Mr. Cheffo has also handled numerous toxic and environmental exposure suits.

Mr. Cheffo has taken part in several trial teams in high-profile pharmaceutical litigation, managing all stages of a dispute from negotiation, through pre-trail proceedings to trial. In addition to defending expert and company witness depositions, Mr. Cheffo has briefed and conducted numerous Daubert and Frye challenges. He has also briefed and argued dispositive motions and appeals in state and federal courts throughout the United States. Mr. Cheffo also has considerable experience conducting arbitrations and mediations relating to disputes.

Memberships

New York City Bar Association; International Association of Defense Counsel

Education

Stony Brook University, B.A., with Honors, 1987, Pi Sigma Alpha National Political Science Honor Society, Phi Alpha Theta International History Honor Society; Boston University School of Law, J.D., 1990, Editor-in-Chief of American Journal of Law & Medicine, Paul J. Liacos Scholar

Lawyer Rankings

United States > Dispute resolution > Product liability, mass tort and class actions: pharmaceuticals and medical devices - defense

(Leading lawyers)

Mark CheffoDechert LLP

Highly regarded in the pharmaceutical space, Dechert LLP is particularly experienced in handling product liability, mass tort and class actions for manufacturers and distributors. Jointly led by New York-based Sheila Birnbaum and Mark Cheffo, the team is representing Purdue Pharma as national counsel in over 1,400 cases regarding its prescription opioid medication, and is defending Pfizer as lead national counsel in litigation relating to the antidepressant Zoloft, which allegedly causes birth defects in children when taken during pregnancy. The practice group also continues to represent AbbVie in national product liability litigation involving testosterone replacement therapy AndroGel, including an MDL in Chicago in which Nathan Hoffman takes the co-trial counsel role. Moreover, the team is acting as lead appellate counsel for Johnson & Johnson in the mass tort litigation claiming personal injury from use of anti-psychotic medication Risperdal. Philadelphia-based Ben Barnett and Douglas Fleming in New York are other key members of the practice group.

United States > Dispute resolution > Product liability, mass tort and class actions: toxic tort - defense

Dechert LLP is well known for representing pharmaceutical companies in chemical exposure claims, and also has experience in water contamination matters. Sheila Birnbaum and Mark Cheffo, who jointly head the team from New York, are defending Pfizer in product liability litigation relating to the antidepressant Zoloft, which allegedly causes birth defects in children when taken during pregnancy; the duo is also acting for Purdue Pharma in multiple cases concerning opioid medication. Los Angeles-based William Oxley continues to act as lead trial counsel for Union Carbide in asbestos litigation across the US. Nathan Hoffman in Chicago and Hope Freiwald in Philadelphia are also recommended.

United States > Industry focus > Healthcare: life sciences

The ‘highly creative’ practice at Dechert LLP is co-headed by Andrea L C Reid in Boston and David S Rosenthal in New York, who focus on IP and corporate work respectively. Reid advised clinical-stage biopharmaceutical company PureTech Health on IP-related aspects of its deal with Hoffman-La Roche to advance its milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform. Rosenthal has assisted Egalet with an asset purchase agreement to acquire four FDA-approved, non-narcotic pain products from Iroko. Product liability litigators Sheila Birnbaum and Mark Cheffo, who joined the New York office from Quinn Emanuel Urquhart & Sullivan, LLP in July 2018, have been acting for Purdue in over 1,400 cases related to its prescription opioid pain medications. Patent specialist Chad Davis from Goodwin is another recent arrival in Boston. The ‘incredibleCarl Morales in New York, who is experienced in developing and prosecuting patent portfolios for FDA-approved or soon-to-be approved drug products, is also recommended.